long intergenic non-protein coding RNA 2847Genealiases: []
Q-omics provides the consensus-scored LINC02847 profile across patient tissues and cancer cell-line models. LINC02847 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC02847 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, LINC02847 RNA expression shows 9,768 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, BRCA, and TGCT as cancer lineages where LINC02847 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02847 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02847 survival associations across molecular data types. LINC02847 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02847 RNA expression–survival associations across cancer types. High LINC02847 expression shows unfavorable associations in LUAD, THCA, LGG, READ and UCEC, but favorable associations in LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC02847 RNA expression.
This table summarizes LINC02847 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02847. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02847 shows lower tumor expression in BRCA, UCEC, LUAD, CHOL and BLCA and higher tumor expression in HNSC. The BRCA box plot shows higher LINC02847 RNA expression in normal versus tumor tissue (log2 FC = −0.321, t-test p < 0.001).
This table shows molecular features associated with LINC02847 in patient tissues and cancer cell lines. In patient samples, LINC02847 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
